Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. Oktober 2025 07:00 ET | Quelle: Amphista Therapeutics

Amphista Therapeutics to showcase how its Targeted Glue™ technology is expanding the diversity of TPD medicines at the 8th Annual TPD & Induced Proximity Summit 2025

Presentation will showcase the novel mechanisms of degradation of Amphista's Targeted Glues™, which recruit diverse E3 ligases, including DCAF16 and FBXO22, expanding the diversity and opportunity...
16. Juli 2025 07:00 ET | Quelle: Amphista Therapeutics

Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue™ degraders for oncology and immunology indications Cambridge, UK, 16 July 2025 – Amphista Therapeutics (“the Company” or...
03. September 2024 07:00 ET | Quelle: Amphista Therapeutics

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein...
03. September 2024 03:00 ET | Quelle: Amphista Therapeutics

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer

Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein...